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Background: The effect of antiplatelet agents for the treatment of acute stroke is less certain than that for
the treatment of acute myocardial ischemia. In this study, we investigated whether antiplatelet agents
(aspirin, clopidogrel, and ozagrel) demonstrated a favorable effect on functional outcome and cognitive
status 3 months poststroke.
Methods: We randomly selected 24 hospitals from ﬁve different regions in China. Patients without
recurrent stroke were recruited and neurological and neuropsychological examinations were performed
on these patients at 3 months poststroke. Each patient was diagnosed as having favorable or poor
functional outcome and normal cognition or cognitive impairment. Multivariate logistic regression an-
alyses adjusted for sex, age, education, and neurological deﬁcit at stroke onset were performed to
examine whether antiplatelet agents exhibited a favorable effect on functional outcome and cognitive
status at 3 months poststroke.
Results: Of the 518 eligible patients (aged 45e86 years, mean 63.01 ± 9.99 years), 167 (32.2%) were fe-
male. On the basis of univariate analysis, there were signiﬁcant associations between functional outcome
(p ¼ 0.048) and cognitive status (p ¼ 0.026) at 3 months poststroke and the use of antiplatelet agents in
acute ischemic stroke. The adjusted odds ratio for favorable functional outcome was 1.81 (95% conﬁdence
interval: 1.09e2.99) and for normal cognition 1.67 (95% conﬁdence interval: 1.02e2.74).
Conclusion: The use of antiplatelet agents in acute ischemic stroke may have a favorable effect on
functional outcome and cognitive status in patients at 3 months poststroke.
Copyright © 2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
It is well known that antiplatelet agents, including aspirin and
clopidogrel, play an important role in the prevention of myocardial
and cerebral infarctions1,2 and can improve the prognosis of acutere that they have no conﬂicts
of Neurology, Peking Union
ical Sciences, 1 Shuaifuyuan,
a.
n (Z. Zhang).
tric Emergency & Critical Care Memyocardial infarction3. Previous clinical trials have evaluated the
potential use of antiplatelet agents in acute ischemic stroke;
however, these trials showed a nonsigniﬁcant trend in the
improvement of functional outcome in stroke survivors4,5. The
usefulness of antiplatelet agents for the treatment of acute stroke is
less certain than that for the treatment of acute myocardial
ischemia.
Although vascular dementia was very common6, and our pre-
vious study showed cognitive impairment in patients poststroke7,
thus far, few clinical trials have examined cognitive status as an
outcome measure of stroke5,8. Moreover, no clinical trials have
investigated the cognitive effects of antiplatelet agentdicine. Published by Elsevier Taiwan LLC. All rights reserved.
Y. Zhang et al.190administration in acute stroke. Therefore, the aim of the present
study was to examine the effectiveness of antiplatelet agents in
patients with acute ischemic stroke on functional outcome and
cognitive status at 3 months poststroke independent of de-
mographic factors and neurological deﬁcits at stroke onset.
2. Material and methods
2.1. Participants
We selected ﬁve regions that differed in geography and econ-
omy: northeast China, northern China, western China, central
China, and southeast China. We randomly selected 24 hospitals
from these ﬁve regions.
Patients with an acute ischemic stroke were admitted to the
neurology department in the selected hospitals. The patients were
screened between April 1, 2009 and April 30, 2010. Diagnosis of
ischemic stroke was made on the basis of the presence of a sudden
focal deﬁcit and an associated lesion, as assessed using computed
tomography or magnetic resonance imaging. Patients were eligible
for participation in the study if they had experienced ﬁrst-time
ischemic stroke and had received treatment within 7 days of
stroke. Patients were excluded on the basis of the following criteria:
age < 45 years; demonstrated prestroke cognitive impairment
[considered as a score of 55 on the short Informant Questionnaire
on Cognitive Decline in the Elderly (s-IQCODE)]9; or a history of
concomitant cerebral and/or psychiatric disease that was likely to
affect cognition, usefulness of intravenous recombinant tissue-type
plasminogen activator (rt-PA) or contraindications for antiplatelet
agents.
2.2. Collection of clinical data
The following variables were recorded for each eligible patient:
demographics (sex, age, and years of education), neurological ex-
amination and medication in acute and convalescent phases of
stroke. Older age was deﬁned as  65 years. A low education level
was deﬁned as < 7 years of education. The National Institutes of
Health Stroke Scale (NIHSS) was determined at onset and at 3
months poststroke10. Severe neurological deﬁcit upon admission
and at 3 months poststroke were individually deﬁned as the NIHSS
total scores  6 and  2, respectively11. Severe aphasia was deter-
mined as a language item score of NIHSS  2.
2.3. Evaluation of cognitive status
Prior to the formal interview, 48 neurological doctors from 24
hospitals were trained to perform the neurological and neuropsy-
chological tests used in this study. The interviewers' inter-rater
reliability for the cognitive tests exceeded 0.85. All patients
without a disturbance in consciousness, severe aphasia, bilateral
impaired movement, neglect, or recurrent stroke at 3 months
poststroke were recruited for the study, and a battery of neuro-
psychological tests were performed on the patients. First, the pa-
tients underwent cognitive screening using the Montreal Cognitive
Assessment with a cut-off score of 2612. To conﬁrm cognitive
impairment after stroke, the patients who did not pass the cogni-
tive screening were asked to complete a battery of cognitive tests
that lasted for approximately 30 minutes and covered four major
cognitive domains: memory, which was assessed using the Fuld
Object Memory test13; executive function, which was assessed
using the Rapid Verbal Retrieve test14; visuospatial ability, which
was examined using the Block Design subset of Wechsler for Adult
Intelligence Scale-Revised15; and attention, which was measured
using the Digit Span subset of the Wechsler for Adult IntelligenceScale-Revised15. These tests were selected because they do not
require literacy for a successful performance.
2.4. Outcome measures
The cognitive outcome was assessed using previously described
neuropsychological examinations. A deﬁcit was deﬁned as a per-
formance below the 10th percentile relative to the education-
adjusted normalized data. The limit scores for these tests have
been previously established in several large surveys related to de-
mentia in China16,17. In this study, the diagnosis of cognitive
impairment after stroke was made according to the diagnosis
criteria of vascular cognitive impairment18 in patients who suffered
from a stroke and exhibited a subsequent impairment in at least
one cognitive domain. Patients without impaired cognitive func-
tion were classiﬁed as having normal cognition. An experienced
neurologist determined the ﬁnal diagnosis after a thorough ex-
amination of all of the clinical and neuropsychological data.
The modiﬁed Rankin Scale is a simpliﬁed overall assessment of
function in which a score of 0 indicates the absence of symptoms
and a score of 6 indicates death. Scores within 1 on the modiﬁed
Rankin Scale indicate a favorable functional outcome8.
2.5. Ethics
The protocols used in this study were approved by the ethics
committees of all of the selected hospitals. Written informed con-
sent was obtained from all of the patients or their legal guardians
before any interviews were conducted.
2.6. Statistical analysis
All of the statistics were analyzed using SPSS version 13.0 for
Windows (SPSS Inc., Chicago, IL, USA). The primary aim of the an-
alyses was to compare the prevalence of a favorable functional
outcome and normal cognition at 3months poststroke between the
patients treated with and without antiplatelet agents. Thus, we
calculated the crude and adjusted odds ratios (OR) with corre-
sponding 95% conﬁdence intervals (95% CI) using logistic regres-
sion. We adjusted for sex, age, level of education, and neurological
deﬁcit at stroke onset. A p value < 0.05 was considered signiﬁcant.
3. Results
A total of 701 patients with acute stroke were screened. Upon
admission, 85 patients were excluded because they were either
younger than 45 years (16 cases); transient ischemic attack (16
cases), prestroke cognitive impairment (27 cases), cerebral disease
or mental disorder (23 cases); or received intravenous rt-PA (3
cases). At the follow-up evaluation, 98 patients were excluded due
to refusal (50 cases), death (3 cases), recurrent stroke (7 cases),
severe aphasia (23 cases), or missing data (15 cases).
Of the 518 eligible patients (aged 45e86 years with a mean age
of 63.01 ± 9.99 years), 167 (32.2%) were female, and 263 (50.8%)
were admitted to the hospital within the ﬁrst 48 hours of stroke
onset. The average stay in the hospital was approximately 2 weeks.
There were no signiﬁcant differences in sex, age, or neurological
deﬁcit at stroke onset between patients whowere treated with and
without antiplatelet agents; however, patients with a high educa-
tional level were more likely to take the antiplatelet agents
(Table 1).
Of the patients who were taking antiplatelet agents, 330 (75.9%)
were administered with aspirin (dose 100e300 mg), 64 (14.7%)
were taking clopidogrel (dose 75e300 mg), 32 (7.4%) were given
dual antiplatelet agents (aspirin and clopidogrel), nine (2.1%) were
Table 1
Characteristics of the study population.
Characteristic Antiplatelet agents All patients
(n ¼ 518)
c2 p
Yes
(n ¼ 435)
No
(n ¼ 83)
Sex 2.558 0.110
Female 134 (30.8) 33 (39.8) 167 (32.2)
Male 301 (69.2) 50 (60.2) 351 (67.8)
Age group 0.747 0.387
45e<65 y 245 (56.3) 51 (61.4) 296 (57.1)
 65 y 190 (43.7) 32 (38.6) 222 (42.9)
Education years 3.954 0.047
< 7 130 (29.9) 34 (41.0) 164 (31.7)
 7 305 (70.1) 49 (59.0) 354 (68.3)
NIHSS score at
stroke onset
1.318 0.251
< 6 337 (77.5) 69 (83.1) 406 (78.4)
 6 98 (22.5) 14 (16.9) 112 (21.6)
NIHSS score 3 months
poststroke
0.044 0.833
< 2 283 (65.1) 53 (63.9) 336 (64.9)
 2 152 (34.9) 30 (36.1) 182 (35.1)
Cognitive status
3 months poststroke
6.062 0.014
Normal 320 (73.6) 50 (60.2) 370 (71.4)
Impaired 115 (26.4) 33 (39.8) 148 (28.6)
Functional outcome 4.445 0.035
Independenta 331 (76.1) 54 (65.1) 385 (74.3)
Dependentb 104 (23.9) 29 (34.9) 133 (25.7)
Data are presented as n (%).
NIHSS ¼ National Institutes of Health Stroke Scale.
a Independent ¼ modiﬁed Rankin scale mRS <2.
b Dependent ¼ modiﬁed Rankin scale 2.
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tinal adverse effect of oral antiplatelet agents, and 43 (8.3%) were
taking both oral antiplatelet agents (aspirin and/or clopidogrel) and
intravenous antiplatelet agents (ozagrel).
A favorable functional outcome at 3 months poststroke was
observed in 331 patients (76.1%) whowere treatedwith antiplatelet
agents versus 54 patients (65.1%) who were not treated with anti-
platelet agents (p ¼ 0.035). Normal cognition was found in 320
(73.6%) and 50 (60.2%) of these patients, respectively (p ¼ 0.014).
Therapy with antiplatelet agents demonstrated a positive effect on
functional outcome (adjusted OR: 1.81, 95% CI: 1.09e2.99) and
cognitive status (adjusted OR: 1.67, 95% CI: 1.02e2.74) in these
patients (Table 2).
To exclude the effect of antiplatelet agents at the convalescent
phase of stroke on functional outcome and cognitive status at 3
months poststroke, the number of patients (out of 518 total pa-
tients) who took antiplatelet agents at the convalescent phase of
stroke was recorded. In total, 482 patients (93.1%) had taken anti-
platelet agents, which was signiﬁcantly more than the 438 patients
(84.6%) who took the antiplatelet agents during the acute period of
stroke. Nevertheless, there were no associations between the use of
antiplatelet agents at the convalescent phase of stroke and theTable 2
Crude and adjusted associations between the use of antiplatelet agents in acute
ischemic stroke and outcome at 3 months poststroke.
Outcome Crude relationship Adjusted relationshipa
OR (95% CI) p OR (95% CI) p
Favorable functional
outcome
1.55 (1.04e2.33) 0.035 1.81 (1.09e2.99) 0.022
Normal cognition 1.65 (1.10e2.45) 0.014 1.67 (1.02e2.74) 0.042
a Adjusted for sex, age, level of education, and National Institutes of Health Stroke
Scale at stroke onset.functional outcome and cognitive status at 3 months poststroke
(p > 0.05).
4. Discussion
Antiplatelet agents can signiﬁcantly reduce the risk of recurrent
myocardial and cerebral infarctions1,2 as well as improve the
prognosis of acute myocardial infarction3. However, data reﬂecting
the effect of antiplatelet agents on acute stroke have been too
limited to support any strong conclusions. We used univariate
analysis to determine whether patients taking antiplatelet agents
in acute ischemic stroke demonstrated a favorable functional and
cognitive outcome. Our results were consistent despite controlling
for the effects of sex, age, educational level, and neurological deﬁcit
at stroke onset. Furthermore, to avoid the effect of the usefulness of
antiplatelet agents during the convalescent period on the stroke
prognosis, we analyzed the associations between the use of anti-
platelet agents at the convalescent period of stroke and the func-
tional and cognitive outcome at 3 months poststroke and found no
associations (p > 0.05). Through this study, we suggested that the
use of antiplatelet agents in acute ischemic stroke may improve the
prognosis of stroke survivors.
Two large trials have independently demonstrated a nonsig-
niﬁcant trend in reducing death or disability onset and a minor
increase in bleeding complications when treatment with aspirin
was initiated within the ﬁrst 48 hours of stroke4,5. When the data
from the two trials were combined, a modest but signiﬁcant beneﬁt
was observed with aspirin therapy. It is still unclear whether
treatment with aspirin improved the neurological consequences of
the acute stroke itself4, although the most recent guidelines
regarding early management of patients with acute ischemic stroke
state that this primary effect was most likely attributed to the
prevention of recurrent events. However, our study obtained con-
ﬂicting results to those previously described, whichmight be due to
the participants of this study, who were stroke survivors and only
had a rather minor neurological deﬁcit at stroke onset (NIHSS from
0 to 17, median 3). These data suggest that antiplatelet agents
should be applied to stroke patients without very severe neuro-
logical deﬁcits.
Several previous studies related to the treatment of acute stroke
have focused solely on the neurological deﬁcit or functional
outcome as outcome measures and not on cognitive status5,8.
Although only two clinical studies, to date, have measured cogni-
tion, patients taking rt-PA or antiplatelet agents have not demon-
strated a favorable cognitive outcome19,20. However, our study
demonstrated that the use of antiplatelet agents in acute strokewas
markedly associated with a favorable cognitive outcome, which
may be due to the rigorous research methods applied in our study.
For example, we excluded the patients with recurrent stroke and
prestroke cognitive impairment and adopted a standard method to
diagnosing cognitive impairment.
In this study, we demonstrated a positive effect of antiplatelet
agents in acute ischemic stroke on the functional and cognitive
outcome at 3 months poststroke. Two potential explanations may
underlie this ﬁnding. On the one hand, antiplatelet agents in an
acute ischemic strokemay exert neuroprotective mechanisms21. On
the other hand, the use of antiplatelet agents in acute ischemic
stroke contributes to the recanalization and salvage of penumbra, a
process known as the diffusioneperfusion mismatch22,23. The
duration and extent of the penumbra in acute ischemic stroke
determine the treatment window, thereby inﬂuencing the poten-
tial for interventions to save injured tissue after stroke. Most of
studies considered that the time window of the penumbra only
lasts for several hours1, however, because some studies have
revealed that hypoxia within the penumbra might persist for
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lower bleeding risk compared to rt-PA, so antiplatelet agents can
provide with sufﬁcient time to ameliorate stroke damage. On the
whole, it seems likely that the second reason, the recanalization of
penumbra in acute ischemic stroke, is the key explanation for the
positive effect in this study. The antiplatelet agents only played a
preventive role at the convalescent phase of stroke, which
contributed to there being no associations between the use of an-
tiplatelet agents at the convalescent phase of stroke and the func-
tional outcome cognitive status at 3 months poststroke in this
study (p > 0.05).
It was astonishing that we found that many patients in the study
did not take antiplatelet agents at the acute and convalescent phase
of stroke, and patients with a low educational level were less likely
to take antiplatelet agents. There may be two key reasons: (1)
because the patients who did not take antiplatelet agents generally
had a low educational level, their drug compliance was poor; and
(2), due to the low medical level in some regions, some doctors in
this study did not know that the use of antiplatelet agents could
improve the prognosis of stroke survivors at the acute phase of
stroke and could play a preventive role at the convalescent phase of
stroke, therefore, they did not prescribe antiplatelet agents to pa-
tients with ischemic stroke, especially at the acute phase of stroke.
Finally, there are some limitations with the cognitive scales in
the study. Although s-IQCODE is proposed to obtain premorbid
history of the cognitive status26 and the scale has been shown to be
adequate for detecting changes from prestroke cognitive status27,
we must be aware of that some informants may be subjective and
dishonest in the survey. In addition, when the cutoff of Montreal
Cognitive Assessment is < 26, the sensitivity and speciﬁcity for
detecting cognitive impairment are individually 0.87 and 0.6328.
Therefore, some patients with cognitive impairment were mis-
diagnosed as having normal cognition in this survey.
Because this is a retrospective observational study, we can only
conclude that the use of antiplatelet agents in acute ischemic stroke
may have a favorable effect on functional outcome and cognitive
status 3 months poststroke. To further conﬁrm these conclusions,
double-blind controlled studies on the dose-effect and time-effect
relationship should be performed.
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